Wednesday, September 30, 2026

When Every Minute Counts: Rethinking aHUS Care in India

This article was written by Linda Burke, one of the senior-most aHUS patient advocates in the world and trustee of the aHUS Alliance Action. This article builds on a discussion initiated by Dr. Manisha Sahay during the webinar held on aHUS Awareness Day in September 2026.

--------------------------------------------------


A Disease That Doesn't Wait

Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening blood disorder. For patients, getting the right diagnosis fast can mean the difference between full recovery and permanent organ damage. The good news is that basic lab tests for aHUS are widely available across India. The real problem isn't access to common labs — it's the delay in getting specialized testing done and waiting for results like complement panels or genetic testing to come back. In a disease that can cause rapid kidney failure or damage to major organs like the heart or brain, that delay is life-threatening.

Why Centers of Excellence Aren't Enough on Their Own

India's healthcare system increasingly relies on Centers of Excellence (CoEs) — hospitals or institutes that concentrate top specialists, advanced technology, and rare-disease expertise in one place. For a condition like aHUS, this concentration is genuinely valuable: it means better-trained doctors, cutting-edge diagnostics, and consistent treatment standards.

But CoEs come with a built-in weakness: geography. Most are located in major cities, which is a serious problem for patients in remote or rural regions. Getting to a CoE — and back again for the follow-up visits that rare-disease and clinical-trial care requires — means long travel times, real financial cost, and lost wages. For a patient in the middle of an aHUS crisis, that travel time is exactly what they don't have.

The Hub-and-Spoke Model

One model gaining attention in healthcare planning is the "hub-and-spoke" system, borrowed from aviation and logistics. The idea is simple: keep the most advanced, expensive resources centralized at one main Hub (such as a CoE), while a network of smaller local sites — the ‘Spokes’ — handle initial evaluation, routine care, and triage close to where patients live.

If a spoke-level patient needs more advanced care, in some nations they're transferred to the hub. In India or other nations with limited healthcare resources, this is unlikely. A patient with a suspected diagnosis of aHUS at a rural hospital might encounter a physician familiar with this rare disease, and basic lab tests can be performed locally - but what happens next? 

Here's how the two models compare:

Why This Matters Specifically for aHUS

Applying this model to aHUS could directly address the diagnostic delay that's the real bottleneck today. Rather than requiring every patient to physically reach a CoE for specialized testing, a spoke-and-hub network could allow:

  • Local hospitals to draw and ship samples for rapid specialized testing, rather than requiring patient travel
  • Faster turnaround on results through better-coordinated logistics between spoke and hub
  • Remote consultation with aHUS specialists at the hub while the patient stays close to home
  • Local clinics supporting ongoing monitoring and trial-related check-ins, reducing repeat travel to the CoE

The Catch: It Only Works If the System Holds Together

A hub-and-spoke model isn't a free lunch. It depends entirely on one "operating system" working well. If the hub gets overwhelmed with cases that didn't need to be there, or if the digital infrastructure connecting spokes to the hub breaks down, the whole network suffers. Making this work in India would require real investment in two things: unified digital medical records that let hub specialists see spoke patient data instantly, and reliable transport logistics for the cases that do need to move.

The Bottom Line

Centers of Excellence remain essential for aHUS — they're where research, training, and the deepest expertise live. But for a disease where speed of diagnosis determines outcomes, relying on CoEs alone leaves patients in remote parts of India dangerously exposed to delay. A hub-and-spoke model, built on strong digital connectivity and transport logistics, offers a realistic path to bringing rapid aHUS diagnosis closer to where patients actually are.

 

aHUS Awareness Day 2026 Webinar - Summary and Key Takeaways

Atypical haemolytic uraemic syndrome (aHUS) can be diagnosed with simple tests and treated effectively, but in India too many patients reach the right doctor after the window to save their kidneys has closed. That was the common thread of the aHUS Awareness Day webinar we hosted online on 24 September 2026.

Why this webinar mattered

24 September is observed worldwide as aHUS Awareness Day. The day was started in 2015 by the aHUS Alliance, a global coalition of patient groups, and 2026 marks its 12th edition. It exists to raise visibility for a disease that most people, and many doctors, have never heard of.

Our founder Kamal Shah, who is also co-founder of NephroPlus, opened the session with his own story. He fell ill in 1997, aged 21, days before leaving to pursue his master's. It took time before anyone named the disease. A transplant in 1998 lasted only weeks before aHUS recurred, and he has now been on dialysis for almost 29 years.

aHUS affects roughly one or two people in a million. In a country of India's size that is still a great many families. For most of them, Kamal said, the story is one of delayed diagnosis, missed treatment windows, or a therapy that exists but is financially out of reach. Each of these is solvable, and none will be solved in silence. He framed the evening not as a commemoration but as a working session.

We organised the webinar with support from PatientsEngage, AstraZeneca and NephroPlus, and it was hosted by Aparna Mittal, founder and CEO of PatientsEngage. We were privileged to bring together five of the country's leading nephrologists and a patient speaker.

Recognising aHUS: every hour counts

Dr Arvind Bagga, who established the Indian HUS registry at AIIMS New Delhi and is now Director of Pediatrics at Indraprastha Apollo Hospitals, spoke on diagnostics from the patient's point of view.

What doctors look for. aHUS usually shows up as three problems at once: kidneys that suddenly stop working well, a low blood count (anaemia), and low platelets, the blood cells that help clotting. A simple blood test called a peripheral smear can show broken red blood cells under the microscope. Together, these point strongly to HUS.

Ruling out look-alikes. Many common illnesses, such as malaria, dengue, severe infections and lupus, can look similar. A good doctor checks for these first. If you or your family member is being treated, it is fair to ask whether other causes have been considered.

Other routine tests. Doctors will usually also check complement levels (complement is the part of the immune system that goes wrong in aHUS), a blood test called LDH that shows red cells breaking down, and a urine test. They may check the heart and pancreas too.

Genetic testing. Once other causes are ruled out, a genetic test is recommended, especially if long-term treatment is being planned. Good Indian labs now return results in about three weeks, and kidney specialists can usually explain the report without a separate geneticist.

Why speed matters so much. Everyone knows a heart attack or stroke is an emergency. Dr Bagga said aHUS deserves the same urgency. The chance to save the kidneys lasts only about 12 to 48 hours. Treatment should start straight away, either with the medicine eculizumab or with plasma exchange (a procedure that filters and replaces the plasma in the blood), without waiting for genetic results.

Two reassuring messages. First, eculizumab does not always have to be taken for life. Many patients can try stopping after about six months, with a plan to restart quickly if the disease returns. Second, carrying a gene change linked to aHUS does not mean you will definitely get ill.

A form common in Indian children. Many children aged about 4 to 17 have a type called anti-factor H antibody disease, where the body makes antibodies against one of its own protective proteins. This type responds well to two to three weeks of plasma exchange along with medicines that calm the immune system.

What aHUS means for your family

Dr Raja Ramachandran, Additional Professor of Nephrology at PGIMER Chandigarh, answered a question many families ask: if one of us has aHUS, who else is at risk? He walked through five example families, based on real cases with small changes.

His central message was that having a gene change is not the same as having the disease. Even among people with aHUS, the best labs in the world find a gene change in only about 60%. And most people who carry a gene change never become ill. For most aHUS genes, only about one in four carriers ever develops the disease.

The family member

The situation

What it means

A healthy father

He carries two copies of a gene change and has never been ill at 58. His daughter, with only one copy, developed aHUS at 24.

Genes alone do not decide who gets sick. Something else usually has to happen too.

A pregnant daughter

Her mother developed aHUS after giving birth and carries a gene change. She is now expecting her first child.

Pregnancy and blood loss can trigger aHUS. She should be closely watched late in pregnancy and just after delivery.

A healthy uncle

He has the same common gene deletion (CFHR1/CFHR3) as a child in the family with aHUS, but his body makes no harmful antibodies.

He does not need to worry. Up to a third of Indians carry one copy of this deletion with no added risk.

A brother who wants to donate a kidney

He offers a kidney to his brother with aHUS, but carries the same gene change.

Surgery could trigger aHUS in him. Relatives who carry a complement gene change are generally not accepted as kidney donors.

A cousin with two gene changes

A healthy cousin is tested and found to carry two different gene changes.

Carrying more than one change raises the risk a lot, from about one in four to about three in four.

Dr Raja described aHUS as needing several "hits". The first is a gene change. The second is a smaller, common genetic difference that adds risk. The third is a trigger, such as an infection, pregnancy, heavy blood loss, a transplant or certain medicines (for example, tacrolimus and cyclosporine, used after transplants). Most of the time all three are needed before someone falls ill.

If a carrier needs surgery. Kamal asked what someone with a gene change should do if they need an operation. Dr Raja advised keeping blood loss low, preventing infection with antibiotics, and watching closely afterwards for a falling blood count, falling platelets or passing less urine.

A common question from patients. One patient asked whether having one copy of the CFHR1/CFHR3 deletion rules out family donors. Dr Raja and Dr Bagga both said this deletion is found in 30 to 40% of Indians and, on its own, is not linked to aHUS. Families should discuss donor testing with their own transplant team.

The panel: the patient journey and getting treatment

The panel brought together Dr Aditi Sinha (Professor of Pediatric Nephrology, AIIMS New Delhi), Dr Manisha Sahay (Professor and Head of Nephrology, Osmania Medical College, Hyderabad), Dr Narayan Prasad (Professor and Head of Nephrology, SGPGIMS Lucknow) and Kamal Shah.

Why diagnosis is often late

Dr Sinha said every patient's journey is different, depending on which doctor they see first. Some are diagnosed quickly. Others are wrongly told they have long-term kidney disease because nobody did the simple blood smear. Dr Bagga added that many patients reach a specialist only after about two weeks, long after the critical first few days. In countries like the UK and the Netherlands, patients are usually treated within 24 to 48 hours.

The good news is that diagnosis does not need complicated tests. Simple blood and urine tests are usually enough, and a kidney biopsy is rarely needed.

Kamal said the biggest challenge for families is simply reaching a doctor who has heard of aHUS. Even after diagnosis, reliable information is hard to find. Dr Sinha felt that because aHUS is so rare, the priority is teaching doctors to recognise it and refer patients quickly to an experienced kidney specialist.

Why treatment can be hard to get

The main medicine for aHUS, eculizumab, is very expensive. The government's National Policy for Rare Diseases (NPRD) can help pay for it, but only through designated Centres of Excellence and usually only for long-term treatment, not the emergency first doses.

Dr Manisha Sahay spoke for India's roughly 410 government medical colleges, where many ordinary families are treated. These hospitals can diagnose aHUS and start plasma exchange for free, but approval for eculizumab often comes too late to save the kidneys. There are only 16 Centres of Excellence in the country, and one for all of Telangana. She suggested linking medical colleges to these centres in a "hub-and-spoke" network so care is available closer to home.

Dr Sinha and Dr Bagga explained that even at the Centres of Excellence, emergency treatment is not free and is largely paid out of pocket. Dr Prasad said that when families can afford it, he asks them to buy one or two doses early while the NPRD application is processed.

Kamal described our advocacy for keeping a few emergency doses at every Centre of Excellence. Treatment could then start immediately, with funding approval sought afterwards.

Confusion about genetic tests

Kamal said many patients and doctors are unsure whether a genetic test is required. Doctors on the panel agreed it is not needed to start treatment. However, some centres still require it before approving NPRD funding, while others, such as PGIMER Chandigarh, accept the doctor's diagnosis. Dr Bagga noted that most Indian patients do not show a gene change but still deserve treatment. Specialists are working on a shared national statement to clear this up.

Using the medicine wisely

The doctors also cautioned that eculizumab should only be used when it is truly aHUS, not for look-alike conditions. Starting it and then stopping after one or two doses, often for financial reasons, is also a problem. Dr Sinha suggested a quick-response expert team, or "TMA board", to decide on emergency treatment within hours.

A patient asked whether starting treatment before all test results are in is risky. Dr Prasad said eculizumab is generally safe but raises the risk of certain serious infections, such as meningitis. Patients are given antibiotics and vaccinations to protect them.

How the patient community can help

• Dr Sinha: a web page where patients can send questions and be connected to the right expert anywhere in the country.

• Dr Sahay: a system where no family navigates aHUS alone, with help on funding, follow-up care, genetic, transplant and pregnancy counselling, and emotional support.

• Dr Prasad: expert-reviewed FAQs and short videos on social media, and continued efforts to show the government that early treatment costs far less than a lifetime of dialysis.

Lived experience: why peer support matters

Arjun Arora, whose aHUS story is published on our website, closed the programme. He holds a master's in business from Canada and moved back to India after he fell ill. He now runs a plywood manufacturing business in his hometown of Yamunanagar, Haryana.

Arjun said he has met few other aHUS patients. Kamal was the one who gave him hope and encouragement and helped him make sense of his situation. Through that connection he reached Dr Raja, who explained that his heterozygous result is common in the population and may not stand in the way of a transplant. He was later connected with Dr Bagga.

His suggestion for the community was simple: patients can mention aHUS in their social media bios, so that anyone who visits their profile might ask what it is. Aparna Mittal added that every shared story breaks silence and stigma, and helps others realise they are not alone.

Key takeaways for patients and families

1. Treat it as an emergency. Sudden kidney failure with a low blood count and low platelets needs urgent care. The chance to save the kidneys lasts only about 12 to 48 hours.

2. Ask for a kidney specialist early. If aHUS is suspected, ask to be referred to an experienced nephrologist or a Centre of Excellence without delay.

3. Simple tests can confirm it. A blood smear, blood count and urine test are usually enough. A kidney biopsy is rarely needed.

4. Treatment should not wait for genetic results. Genetic tests take about three weeks. They help plan long-term care but should not delay the first treatment.

5. Treatment may not be lifelong. Many patients can try stopping eculizumab after about six months, under their doctor's guidance, with a plan to restart if needed.

6. A gene change is not a diagnosis. Most relatives who carry a gene change never become ill. Illness usually needs a trigger such as infection, pregnancy or surgery.

7. Talk to your doctor about family planning, surgery and donation. Pregnant women with a family history need close monitoring. Relatives who carry a complement gene change are generally not suitable kidney donors.

8. Know the funding routes. NPRD support is available through Centres of Excellence, mainly for long-term treatment. Emergency doses are often paid out of pocket, so ask your team early about options.

9. Finish what you start. Stopping treatment after one or two doses can undo its benefit. Discuss costs and plans with your doctor before starting.

10. You are not alone. Connecting with other patients and families through our community can bring information, hope and practical support.

Looking ahead

Kamal opened the evening with a warning. Somewhere, someone is walking into an emergency room with anaemia, low platelets and failing kidneys, and their outcome may depend on whether the doctor has heard of aHUS. The webinar showed that India now has the expertise, the tests and the treatments. The work that remains is getting them to every patient in time. We will keep pushing for that, alongside doctors, policymakers and families.

If you or someone you know is living with aHUS, you are not alone. Share your story, bring us your questions, and connect with others in our community. The full webinar recording is available on our Atypical HUS India YouTube channel.

(This article summarises an educational webinar and is not medical advice. Please speak to your nephrologist about your own care.)




aHUS Awareness Day Webinar - September 2026

The Atypical HUS India Foundation along with PatientsEngage recently hosted a webinar featuring leading researchers and clinicians specializing in atypical hemolytic uremic syndrome. The webinar was held on September 24, 2026, in recognition of aHUS Awareness Day. 

Here is the webinar recording:



Friday, September 4, 2026

Did you know that a name change is being considered for aHUS?

Did you know that a name change is being considered for aHUS? What impact will that have on all of us as patients? How will this impact national policies? Please read up about this on this link:

https://www.ahusallianceaction.org/can-an-inclusive-composite-name-be-found/

And then make your voice heard by voting where you stand on the name change here:

https://www.ahusallianceaction.org/call-ahus-ctma-community-support-ahus-day/

Saturday, April 4, 2026

Summary for patients of recent meeting between nephrologists and geneticists on optimising aHUS Diagnosis

 

Understanding aHUS: Why Early and Accurate Diagnosis Matters

Atypical hemolytic uremic syndrome (aHUS) is a rare but serious condition that affects the blood and kidneys. Because its symptoms can look like several other illnesses, diagnosing it correctly—and quickly—is very important for saving kidney function and even lives.

This article summarizes key insights from experts in nephrology (kidney specialists) and genetics on how aHUS is diagnosed and managed.


What is aHUS?

aHUS is a disease where small blood clots form in tiny blood vessels, especially in the kidneys. This leads to three main problems:

  • Destruction of red blood cells (anemia)

  • Low platelet counts (affecting clotting)

  • Kidney injury

Most cases of aHUS are caused by problems in the body’s complement system, a part of the immune system that helps fight infections. When this system becomes overactive, it can damage the body’s own blood vessels.


Why is Diagnosis Difficult?

The symptoms of aHUS are similar to many other conditions, such as:

  • Severe infections (like sepsis or dengue)

  • A related condition called TTP

  • Diarrhea-related HUS (common in some countries)

  • Autoimmune diseases

Because of this, doctors must first rule out these other conditions before confirming aHUS. 


How Do Doctors Diagnose aHUS?

Doctors follow a step-by-step approach:

  1. Rule out infections and common causes

    Tests are done for infections like malaria, dengue, or bacterial illnesses.

  2. Check for related conditions

    Special tests may be needed to rule out TTP or rare metabolic disorders.

  3. Look for complement system problems

    Blood tests help identify abnormalities in the immune system.

  4. Test for antibodies and genes

    • In many Indian patients, the disease is caused by antibodies against a protein called factor H.

    • Genetic testing may also be done to identify inherited causes.

Importantly, doctors may start treatment before all test results are available, because delays can worsen outcomes. 


Treatment Options

1. Plasma Exchange (Common in India)

This procedure removes harmful substances (like antibodies) from the blood and replaces them with healthy plasma. It is often started urgently.

2. Targeted Medicines

In many countries, drugs that block the complement system (such as eculizumab) are the standard treatment. These drugs can dramatically improve outcomes, but access may be limited in some regions.


Why Early Treatment is Crucial

Experts strongly emphasize that treatment should begin within 24 hours of suspicion. Early treatment can:

  • Prevent permanent kidney damage

  • Reduce the need for dialysis

  • Improve survival


What Makes India Different?

In India, a large number of children with aHUS have a specific type caused by anti-factor H antibodies. This is important because:

  • It is treatable with plasma exchange and medicines

  • Outcomes can be good if treated early


The Importance of Teamwork

Managing aHUS requires a team approach:

  • Nephrologists diagnose and treat kidney problems

  • Geneticists help interpret genetic tests

  • Laboratories ensure accurate testing

Working together helps doctors choose the best treatment and prevent relapses.


Key Takeaways

  • aHUS is rare but serious—early diagnosis is critical.

  • Symptoms can mimic other illnesses, so careful testing is needed.

  • Treatment should start quickly, even before all results are confirmed.

  • Many cases in India are treatable if identified early.

Optimising the diagnosis of aHUS: Meeting of Nephrologists and Geneticists

 A virtual meeting was held between leading nephrologists and geneticists on the 1st April. The meeting was held to arrive at a consensus on diagnosis of aHUS. This was hosted by the Atypical HUS India Foundation and was supported by NephroPlus and AstraZeneca. Here is a video recording of the meeting:

Here is a summary of what was discussed:

Optimising Diagnosis of aHUS: Bridging Nephrology and Genetics

The multidisciplinary meeting brought together nephrologists and geneticists to address a critical challenge in modern nephrology—how to accurately and efficiently diagnose atypical hemolytic uremic syndrome (aHUS). The discussion emphasized the need for a pragmatic, collaborative, and resource-sensitive diagnostic pathway, particularly relevant to India and similar healthcare settings. 

Evolving Understanding of aHUS

A central theme was the changing classification of HUS. Traditionally divided into “typical” (Shiga toxin-associated) and “atypical,” the field is now moving toward a more mechanistic classification:

  • Complement-mediated thrombotic microangiopathy (TMA) (formerly aHUS)

  • Non-complement-mediated TMA

  • Secondary TMAs (e.g., infections, pregnancy, malignancy)

This shift reflects growing evidence that complement dysregulation is the dominant driver in aHUS, with genetic or autoimmune mechanisms underlying most cases. Globally, about 50–60% of cases involve complement pathway abnormalities, particularly mutations in genes such as CFH, CFI, and CD46. 

Interestingly, the Indian context differs: anti–factor H autoantibodies account for a disproportionately large share (up to ~50% in children), especially in the 5–15-year age group.  This epidemiological distinction has major implications for diagnostic prioritization.


Clinical Presentation and Diagnostic Complexity

Clinically, aHUS presents as a thrombotic microangiopathy triad:

  • Microangiopathic hemolytic anemia

  • Thrombocytopenia

  • Acute kidney injury

However, this phenotype is shared across multiple conditions, making diagnosis inherently complex. The discussion emphasized that aHUS is largely a diagnosis of exclusion, requiring systematic elimination of other causes of TMA.


A Stepwise Diagnostic Approach

A consensus diagnostic algorithm was discussed, broadly aligned with international guidelines but adapted for local realities.

1. Exclude Common Mimics

The first step is to rule out conditions that can closely resemble aHUS:

  • Sepsis-associated TMA

  • Tropical infections (malaria, dengue, leptospirosis)

  • Disseminated intravascular coagulation

These are particularly relevant in India and must be excluded early to avoid misdiagnosis. 


2. Evaluate for TTP

In adults especially, thrombotic thrombocytopenic purpura (TTP) must be considered:

  • Severe thrombocytopenia (<30,000)

  • Less prominent kidney injury

  • Multisystem involvement

Diagnosis depends on ADAMTS13 activity assays, which remain limited in availability and costly in India. Proper sample handling (plasma separation and freezing) is critical. 


3. Assess for Shiga Toxin–Associated HUS

Although less common in India, Shiga toxin HUS (STEC-HUS) should be evaluated, especially in cases with:

  • Dysentery or diarrhea

  • Pediatric patients

Diagnostic challenges include:

  • Low yield of stool cultures

  • Need for PCR or antigen-based assays

  • Importance of early sample collection

The key reason for identifying STEC-HUS is that management is largely supportive, unlike aHUS, where aggressive therapy is required. 


4. Screen for Metabolic Causes

An often overlooked but critical category is cobalamin (vitamin B12) metabolism disorders, accounting for 5–10% of cases.

  • Measured via plasma homocysteine

  • Requires early sample storage

  • Highly treatable with targeted therapy

Failure to diagnose these can lead to inappropriate treatment escalation. 


5. Identify Secondary Causes

Secondary TMAs should be evaluated based on clinical context:

  • Autoimmune diseases (e.g., lupus)

  • Malignancy

  • Drug-induced TMA

  • Transplant-associated TMA

  • Malignant hypertension

These are more common in adults and often identifiable through routine investigations. 


Confirming Complement-Mediated aHUS

Once other causes are excluded, attention turns to complement dysregulation, the hallmark of aHUS.

Key Investigations

  1. Complement C3 levels

    • Low in ~40–60% of cases

    • Not universally reliable

  2. Anti–factor H antibodies

    • Particularly important in India

    • High diagnostic yield (~55–57%)

    • Requires robust ELISA methods

  3. Genetic testing

    • Whole exome sequencing (WES)

    • MLPA for structural variants

A key insight was that not all patients require immediate genetic testing. In those with high anti-factor H antibody levels, genetic testing may not add value initially. 


Challenges in Genetic Interpretation

Genetic testing introduces its own complexities:

  • Variants of uncertain significance (VUS)

  • Multiple mutations with unclear relevance

  • Difficulty distinguishing pathogenic vs incidental findings

Clinicians highlighted the need for close collaboration between nephrologists and geneticists to interpret results meaningfully, especially in decisions related to:

  • Long-term therapy

  • Transplant risk

  • Pregnancy counseling


Importance of Early Treatment

A critical consensus point was that treatment should not be delayed while awaiting genetic results.

Treatment Options

  • Plasma exchange (PLEX)

    • Historically standard in India

    • Removes autoantibodies and replaces complement factors

    • Must be initiated within 24 hours

  • Complement inhibitors (e.g., eculizumab)

    • Gold standard globally

    • Dramatically improves outcomes

    • Limited access in India

Early initiation of therapy—especially within 24 hours—was repeatedly emphasized as a determinant of outcomes. 


Indian Context: Unique Realities

The discussion underscored several India-specific challenges:

  • High prevalence of anti-factor H antibody disease

  • Limited access to advanced diagnostics (ADAMTS13, genetic testing)

  • Cost constraints

  • Reliance on plasma exchange over complement inhibitors

Despite these constraints, Indian centers have developed effective adapted protocols, particularly combining plasma exchange with immunosuppression for antibody-mediated disease.


The Need for a Collaborative Model

Perhaps the most important takeaway was the need for integrated care pathways:

  • Nephrologists: clinical suspicion, acute management

  • Geneticists: variant interpretation, long-term risk stratification

  • Laboratories: standardized, reliable assays

The goal is a streamlined, pragmatic diagnostic algorithm that balances accuracy, speed, and feasibility.


Key Takeaways

  • aHUS is primarily a complement-mediated disease, but diagnosis requires systematic exclusion of multiple mimics.

  • Anti–factor H antibody disease is highly prevalent in India, making it a priority test in pediatric patients.

  • Early treatment (within 24 hours) is critical, and should not wait for genetic confirmation.

  • Close collaboration between nephrologists and geneticists is essential, especially for interpreting complex genetic findings and guiding long-term management.


Friday, February 20, 2026

Delays in processing funding applications by CoEs under NPRD

The Government of India has included atypical HUS in its National Policy for Rare Diseases (NPRD). Under this policy, several Centers of Excellence (CoEs) across the country were chosen to handle applications from doctors with patients suffering from these rare diseases for funding treatment to an extent of Rs. 50 lakhs.

Since Soliris became available in India, doctors have been applying for funds allocated for treating aHUS with this drug. Sadly, these applications are not being processed quickly. Atypical HUS is a very serious disease. Because of these delays, patients are either dying or developing kidney failure.

This is unfortunate because the government has provided funds for treating this disease and these funds are not being made available to deserving patients. Due to bureaucratic delays at the CoEs, patients are not getting the treatment they need. This is an appeal to all CoEs to process funding applications for atypical HUS quickly. Delays can endanger patients' lives and lead to death or kidney failure requiring dialysis.

Wednesday, February 11, 2026

Making available vials of Eculizumab to be used in emergencies

The National Programme for Rare Diseases in India has made drugs like Eculizumab available for patients with Atypical Hemolytic Uremic Syndrome. Centers of Excellence (CoEs) have been chosen to handle applications from doctors who need Eculizumab for their patients.

However, these centers are taking a long time to process applications and provide the drug to patients. Atypical HUS is a serious disease that can quickly lead to death or end-stage kidney disease, so delays are dangerous. 

To solve this problem, each center of excellence could keep a few vials of Eculizumab on hand for emergencies. When a patient shows signs of thrombotic microangiopathy, hemolytic anemia, and renal insufficiency - the triad classically associated with aHUS, they can be given the drug right away. This can help prevent kidney failure and stop the disease from getting worse.

For this plan to work, the government and CoEs need to cooperate and ensure that enough vials are available at each center. This way, patients can receive immediate treatment while waiting for further tests to confirm the diagnosis.

The Atypical HUS India Foundation urges the government and CoEs to work together to make this happen.

Monday, November 24, 2025

Webinar Summary for Doctors: Beyond the Illusion: Unravelling the Puzzle of aHUS

A recent multidisciplinary webinar jointly organized by NephroPlus, the Atypical HUS India Foundation and the Kidney Warriors Foundation, with support from AstraZeneca, brought together leading experts in complement-mediated diseases to examine current challenges, evolving strategies, and systemic gaps in the management of atypical hemolytic uremic syndrome (aHUS). Participants included clinicians with extensive experience in adult and pediatric thrombotic microangiopathies (TMAs) such as Dr. Vivekanand Jha, Dr. Arvind Bagga, Dr. Nicole Isbel, Dr. Aditi Sinha, Dr. Manisha Sahay, Dr. Raja Ramchandran, Dr. Sreebhushan Raju, Dr. Sayali Thakare, Dr. Sandhya Suresh and Dr. Arun. The session aimed to distill global experience, regional realities, and clinical insights into a cohesive framework for improving diagnosis and care of complement-mediated TMA in India.

Diagnostic Complexity in Complement-Mediated TMA

One of the recurrent themes was the inherent diagnostic complexity of aHUS and its frequent misclassification in early stages. The syndrome often presents with the familiar triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury—features that overlap significantly with sepsis, malignant hypertension, shiga-toxin–associated HUS, pregnancy-related disorders, and thrombotic thrombocytopenic purpura (TTP). This overlap leads to delayed recognition in peripheral centers, where supportive care is often initiated without a dedicated evaluation for complement-mediated disease.

Experts emphasized that certain patterns should heighten suspicion for complement-mediated TMA: disproportionately severe AKI relative to systemic illness, persistent thrombocytopenia despite clinical improvement elsewhere, markedly elevated LDH, and schistocytosis. Early ADAMTS13 testing was highlighted as a critical step in distinguishing complement-mediated processes from TTP, and several speakers underscored the importance of not allowing the absence of immediate ADAMTS13 results to delay the initiation of diagnostic pathways or consideration of complement blockade.

Importance of Early Complement Blockade

Timely initiation of C5 inhibition remains the single most important modifiable determinant of renal recovery in aHUS. International registries and national cohorts demonstrate that earlier initiation leads to a higher likelihood of renal salvage, fewer long-term dialysis requirements, and lower relapse risk. Plasma exchange, once a mainstay of therapy, is now recognized as potentially counterproductive once complement blockade is initiated, given its impact on drug clearance.

Neurological involvement, while variably reported in literature, was discussed as a marker of severe endothelial injury. In such situations, early and aggressive complement inhibition may help halt progression. Similarly, postpartum TMAs that fail to improve after several days of supportive care may represent complement-driven endothelial injury rather than classical preeclampsia or HELLP syndrome, warranting reconsideration of therapeutic priorities.

Complement Testing and Genetic Evaluation

The webinar highlighted the dual importance and limitation of genetic testing in aHUS. While genetic variants in complement regulators and effectors—such as CFH, CFI, MCP, C3, and CFHR rearrangements—provide valuable prognostic information, their absence does not exclude complement dysregulation. This is especially true in settings where environmental or physiologic triggers such as pregnancy or infections may unmask latent pathway vulnerabilities.

Experts noted the challenges faced in India: variability in assay quality, limited availability of specialized laboratories, long turnaround times for genetic panels, and frequent preanalytical errors in complement sampling. Proper sample handling—rapid processing, cold-chain integrity, and avoidance of complement activation ex vivo—was emphasised repeatedly. Several speakers highlighted that complement levels may appear normal even in active disease due to dynamic consumption, reinforcing the primacy of clinical judgement.

Management of Anti–Factor H Antibody–Associated aHUS

A detailed pediatric case underscored the complexity of managing anti–factor H antibody–mediated aHUS, a phenotype more prevalent in South Asian populations. These patients often present with severe renal injury, very high antibody titers, and substantial complement activation. Effective management requires an integrated approach: plasmapheresis to remove circulating antibodies, immunosuppression (often multi-agent) to suppress antibody production, and complement inhibition to arrest endothelial injury.

Relapses, often triggered by infections, highlight the need for vigilant long-term monitoring. Decisions regarding B-cell–targeted therapies such as rituximab, or newer agents, depend on persistence or rebound of antibody titers. Persistent proteinuria despite hematologic remission remains an important marker of chronic complement-mediated damage, warranting longitudinal nephrology follow-up.

Pregnancy-Associated TMA: Recognizing the Complement Continuum

Pregnancy-associated TMA surfaced as an especially challenging scenario. The clinical overlap with preeclampsia, eclampsia, and HELLP syndrome complicates early diagnosis. However, recurrent episodes across pregnancies, early-onset severe hypertension, precipitous renal injury, or poor fetal outcomes may point towards underlying complement dysregulation. Several experts noted that pregnancy can serve as a physiologic stressor that unmask latent complement pathway abnormalities.

The group discussed the role of prophylactic measures such as aspirin and hydroxychloroquine, which may reduce endothelial activation but do not directly modulate complement activity. In cases where complement-mediated TMA is strongly suspected, early complement inhibition may interrupt the cascade of endothelial injury and improve both maternal and renal outcomes.

Long-Term Management, Relapse Monitoring, and Withdrawal Strategies

The webinar also explored long-term management strategies, including when and how to consider withdrawal of complement blockade. Decisions must incorporate genetic background, disease severity, organ involvement, presence of anti–factor H antibodies, and patient-specific risk factors. Close monitoring after withdrawal—through regular labs, blood pressure tracking, and symptom surveillance—is critical, particularly in patients with complement gene variants or history of relapse.

Relapse risk is highest in the first year after withdrawal and in individuals with pathogenic complement variants. Several experts advocated for structured relapse action plans that empower patients and clinicians to recognize early warning signs and reinitiate therapy promptly.

Building a Better aHUS Care Ecosystem in India

The session concluded with a forward-looking examination of systemic barriers in India. Key needs include: expanding access to complement assays and genetic testing; improving diagnostic capacity in regional hospitals; establishing national registries to track epidemiology, mutations, and outcomes; and developing designated Centers of Excellence with multidisciplinary TMA teams. Strengthening referral pathways and ensuring equitable access to complement inhibition remain high priorities for improving outcomes nationwide.

Key Takeaways

• Complement-mediated TMA is frequently misdiagnosed; early clinical suspicion is essential.

• Early C5 inhibition significantly improves renal recovery and reduces long-term morbidity.

• Genetic testing informs prognosis but must not delay therapy.

• Anti–factor H antibody–mediated aHUS requires integrated immunosuppression, plasmapheresis, and complement blockade.

• Pregnancy-associated TMA often reflects unmasked complement dysregulation.

• India needs improved diagnostic infrastructure, national referral pathways, and Centers of Excellence.

• Long-term follow-up and structured relapse plans are essential due to ongoing risk.


Webinar Summary for Patients: Beyond the Illusion: Unravelling the Puzzle of aHUS

A recent webinar hosted by NephroPlus, the Atypical HUS India Foundation and the Kidney Warriors Foundation, with support from AstraZeneca, brought together leading kidney specialists to discuss atypical hemolytic uremic syndrome (aHUS). This rare and serious condition affects the blood and kidneys and can be difficult to diagnose. Experts including Dr. Vivekanand Jha, Dr. Arvind Bagga, Dr. Nicole Isbel, Dr. Aditi Sinha, Dr. Manisha Sahay, Dr. Raja Ramchandran, Dr. Sreebhushan Raju, Dr. Sayali Thakare, Dr. Sandhya Suresh and Dr. Arun shared their experiences and offered clear guidance on how care can be improved in India.

Why aHUS Is So Hard to Diagnose

One of the biggest challenges with aHUS is that its early symptoms look similar to many other illnesses. Patients often arrive with anemia, low platelet counts, and kidney problems — symptoms also seen in infections, blood pressure emergencies, and pregnancy-related complications. Because these conditions are far more common, aHUS is often not recognized right away.

Certain signs should raise suspicion: kidney injury that seems too severe for the illness, low platelet counts that do not improve, very high LDH (a marker of cell damage), and damaged red blood cells on the blood smear. Early testing to rule out other conditions, especially TTP, is essential. Once these are ruled out, doctors can consider aHUS sooner instead of waiting for symptoms to worsen.

Early Treatment Makes a Major Difference

Early treatment with complement-blocking medicines, most commonly eculizumab, can dramatically improve outcomes. These medicines stop the part of the immune system that causes blood vessel damage in aHUS. Patients treated earlier are much more likely to recover kidney function and avoid long-term dialysis.

Once treatment begins, older approaches such as plasma exchange should usually be stopped because they can reduce the effectiveness of these medicines. Severe symptoms such as confusion or seizures suggest rapidly progressing disease and may require quicker treatment decisions. Similarly, if a woman develops blood vessel damage after childbirth and does not improve within a few days, complement-blocking therapy may be needed.

The Role and Limits of Genetic Testing

Genetic testing can help explain why a person developed aHUS and whether they are at higher risk of relapse. However, a negative genetic test does not rule it out. Many patients have normal results but still have strong signs of complement system overactivity.

Access to high-quality testing remains limited in India, and sample handling errors can give misleading results. Doctors emphasized that treatment should be guided mainly by clinical judgement rather than waiting for test results.

Anti–Factor H Antibody–Related aHUS

Some patients, especially children in South Asia, develop aHUS because their immune system produces harmful antibodies against a protein called factor H. This causes sudden and severe kidney problems. These patients usually need plasma exchange to remove the antibodies, immunosuppressive medicines to control them, and complement-blocking therapy to stop further damage.

Viral infections can trigger relapses even after improvement, so long-term monitoring is important. Ongoing protein loss in urine may indicate that the kidneys still have ongoing injury.

Why Pregnancy Can Trigger aHUS

Pregnancy-related aHUS is especially challenging because it closely resembles complications like preeclampsia or HELLP syndrome. Repeated severe issues across pregnancies, sudden kidney failure, or very low platelet counts may indicate underlying complement problems. In such cases, complement-blocking treatment may help prevent permanent kidney injury.

Long-Term Care and Relapse Prevention

Long-term follow-up after an aHUS episode is essential. Some patients may eventually stop complement-blocking therapy, while others may need longer treatment depending on their condition. Relapses can occur, especially within the first year after stopping treatment. Patients and families should be aware of warning signs and know when to seek immediate help.

Strengthening aHUS Care in India

Experts highlighted several areas where care can be improved: expanded awareness among regional hospitals, easier access to complement and genetic testing, national registries to study patterns of disease, and establishing Centers of Excellence to guide diagnosis and treatment. Better referral pathways and faster access to complement-blocking medicines could make a major difference in outcomes for patients across the country.

 

Webinar Recording: Beyond the Illusion: Unravelling the Puzzle of aHUS

A webinar for doctors was held on the 18th November where leading researchers and clinicians from India and Australia spoke on various aspects of the disease. Here is a recording of the webinar:


You can use this link to share as well: https://www.youtube.com/watch?v=NJX65-UPLdg




Wednesday, October 22, 2025

How you can get access to Soliris (Eculizumab) in India: Government Funding Route

The Government of India has a National Program for Rare Diseases (NPRD) that funds, up to a certain extent, treatment for rare diseases including aHUS. With Soliris (drug name: Eculizumab) now becoming available in India through the company directly, supply should be more reliable. Until now, the drug was available through importers who imported such drugs through unofficial, non-company based channels.

For those who can afford to pay for the drug out-of-pocket, please refer to this post for more details.

This post will outline the steps to take to apply for assistance in procuring the drug through the Government's NPRD.

  • Identify the closest Centre of Excellence (CoE) to you. Here is a complete list of CoEs in India
  • Visit the CoE campus and meet a senior doctor in the nephrologiy department. You may need to take an appointment by phone or in-person. At the time of enrolment, you will be given a Hospital ID. Keep this handy
  • Carry the following with you when you meet the nephrologist:
    • ID proof (Aadhaar / PAN / Voter ID) - original and 2 copies - if patient is a minor, also carry ID proof of parent / guardian
    • 2 Passport size photographs
    • Your medical file that has past prescriptions
    • Any hospitalisation discharge summaries
    • Current Prescription from the nephrologist treating you
    • Recent lab reports - CBP, LDH, Kidney function tests, Urine Analysis etc.
    • Genetic Test Reports, if available
  • The nephrologist may require some other tests to be done or additional documents may need to be provided. Arrange these as requested by them
  • Once all documents are provided, the nephrologist (or their assistant / adminstrator) will enter the details into the NPRD portal. this will include the number of vials, duration of treatment etc. An enrollment number will be generated and given to you. Keep this number safely
  • There is a Rare Disease Committee that has been constituted at each CoE. This committee meets periodically and even on emergency basis to review all applications submitted and decides the merits of each application. The committee meets once every 1-3 months (depending on the hospital and the number of cases to review; they may also meet on emergency basis if needed). The committe decides to approve / reject / recomend to modify the application
  • Once a decision has been reached, you will be notified of the decision
  • Keep in touch with the nephrologist you met about this and any other queries you may have. Sometimes, the nephrologist might put you in touch with another coordinator who would be able to answer any queries you may have
  • The committee may request additional documentation including some investigations. Make sure you get these in a timely manner
  • Also, if you undergo any doctor consults / investigations after the initial form is submitted, make sure you give this to the doctor / assistant in the CoE to submit in the portal
  • Note that approval by the committee might take up to a few months
  • Once the application is approved, then the CoE will raise the funding requisition with the government for which you may be asked to sign some consent forms
  • Once the funding request is approved, the CoE will procure the drug from the company through their pharmacy
  • Once the drug reaches the pharmacy, speak to the nephrologist to discuss the next steps

Please be aware that this is a relatively new process for the CoEs. Even among the CoEs, there are some that are better equipped than others.  Remember, you need to advocate for yourself or your loved one. You will need to keep following up with the relevant stakeholders. Do not expect things to be handed to you on a platter. You will need to push people to help you. Do drop us a line with your experiences and we will do the best we can to help. All the best!

Wednesday, September 24, 2025

Happy aHUS Awareness Day!



September 24th every year is observed as aHUS Awareness Day. The day was picked because it was around that time that the term "Hemolytic Uremic Syndrome" was first used by Prof Conrad van Gasser in medical literature. The day was decided by the Atypical HUS Alliance, an umbrella group of aHUS patient support groups from various nations. 

This year has been special for aHUS patients in India. After years of hopelessness, we finally have a drug that is approved for sale in India and has been launched in India. Until a year or so back, we would never have imagined this would become a reality. Full credit and much gratitude to AstraZeneca for bringing the drug to India! The aHUS India Foundation has witnessed the team work really hard to make this a reality.

The Government of India also deserves a lot of credit for coming out with a National Policy for Rare Diseases. This is truly a sign of tremendous foresight and consideration for rare disease patients. The aHUS India Foundation commends the Government of India for this step on behalf of all aHUS patients.

We are excited that the times are changing for aHUS patients in India. We hope that drug access will be improved further and challenges in pricing will be overcome. We cannot rest until every aHUS patient in the country has access to a drug that they are able to afford and not have to continue to live a compromised life due to this disease.

Here is a message from the aHUS India Foundation on this occasion:




Sunday, September 21, 2025

Changes needed to the National Program for Rare Diseases in India

The Government of India launched the National Program for Rare Diseases (NPRD) a few years back. In its current form, 63 rare diseases (including Atypical HUS) are covered. The program will fund a one time grant of Rs. 50 lakhs to each patient towards treatment. Decisions to fund such treatment will be made by Centres of Excellence (CoE) identified by the government.

Such a policy was unthinkable till a few years back. The debate between spending large sums of money on the treatment of a few people versus spending that money on basic healthcare necessities like preventing infant mortality, basic sanitation and other aspects of primary healthcare which impact several times more people is far from settled. While I may be biased in favour of the former due to my medical history, I do acknowledge that the choice is tricky. I am grateful therefore that the Indian government chose to set up the NPRD which impacts only a few people.

I would still suggest that two changes be made to the NPRD.

One size does not fit all

Currently, irrespective of the disease and the extremely varied types and durations of treatment, the NPRD stipulates the same grant for every patient. While the Rs. 50 lakhs might be more than enough for some, it is woefully inadequate for others. Even within the same rare disease, the requirements could be different. 

Take my disease, aHUS, for instance. Depending on the age of the patient and specific genetic mutation, the dosage and the duration of treatment with Eculizumab (the only approved drug to treat the disease) could vary. Some people would need only two vials twice a month while others could need three to four vials twice a month. Again, some patients may need it lifelong while others could need it only for a few months.

Keeping this reality in mind, the NPRD needs to allocate different funds for different patients. I understand this could make the decision process extremely complex. Who decides, for instance, which patient gets how much money? A group of experts can be constituted for each disease and a framework can be established to guide such decisions. Other solutions can be explored based on the experience of other nations where these problems have been successfully resolved.

Involvement of CoEs

In the current policy, decisions pertaining to applications for assistance under the NPRD are to be taken by CoEs. One can only imagine the delays this would bring about in getting access to the drugs by patients. The process would involve the treating physician getting the history and the clinical summary ready and then getting this information to the appropriate committee in a CoE close by. The authorities who decide on such applications in the CoE would need to then meet and review the dossier submitted. They might have further questions which would need to be communicated to the treating physician and then if everything is clear, they would decide. 

In diseases such aHUS, time is critical. Quick administration of the drug can mean the difference between remission and progression to kidney failure or even death. In such circumstances, does it really make sense to allow so much delay in deciding on the application?

One possible solution could be to not require a committee but one doctor among a panel of doctors in the CoE to decide on the application. The treating physician should be able to request urgent hearing of the case and decisions should be taken in less than 48 hours. Such models have been adopted in other nations already where similar circumstances exist.

The Government of India has shown amazing foresight and consideration for rare disease patients in coming up with the NPRD. If the kinks mentioned above can be ironed out, it would do tremendous benefits to the intended beneficiaries of this policy. 


Friday, September 19, 2025

How you can get access to Soliris (Eculizumab) in India: Self Pay Route

Now that Soliris is available in India, it is important for patients and their families and doctors to know how to get access to the drug. It is obviously not something that you can walk into a pharmacy and buy.

The drug can be accessed on one of two ways:
  1. Paying yourself for it
  2. Getting it through the Government's National Program for Rare Diseases (NPRD)
You can get more information of the contours of the NPRD and how it works here.

The Atypical HUS India Foundation has consulted the manufacturers of the drug and understood the steps to be taken by patients or their families to get access to the drug.

Cost of the drug for self-paying patients

The drug comes in vials of 300 mg each. Each vial costs about Rs. 95,000-100,000. Adults require about 3-4 vials each time, typically twice a month at steady state. There is a higher dosage required in the first few weeks. The dosage for children is typically lower. Please consult your doctor to determine the right dosage and frequency.

Steps to follow to get access to the drug
  • The first step is to speak to your doctor to prescribe the drug on a prescription note along with the history and the tests conducted to make the decision to prescribe. Your doctor will need to ascertain your clinical condition to confirm if the drug is likely to help you. A lot will depend on your current clinical condition including (and not limited to) the following:
    • Are you recently diagnosed and you still retain significant kidney function?
    • Have you progressed to kidney failure requiring dialysis?
    • Are you a candidate for a kidney transplant?
    • Do you have willing related donor?
    • Are you on the cadaver transplant list?
  • Once the prescription is ready, your doctor will need to contact AstraZeneca. The Atypical HUS India Foundation can also help make this connection. Email us at ahusindia@gmail.com.
  • The company's medical team will then speak with the doctor directly to understand the clinical background and requirements.
  • The AstraZeneca commercial team will then liaise with the doctor / hospital pharmacy and arrange the drug through the appropriate authorized distributor.
  • Escalation for urgent support: If you face challenges in accessing the drug, or if the physician is temporarily unavailable, you can write to med.info3@astrazeneca.com with a cc to ahusindia@gmail.com and oshin.santoshi@astrazeneca.com.

We will soon publish steps to access the drug through the second pathway - through the government's NPRD.


Tuesday, September 16, 2025

How India's National Program for Rare Diseases can help aHUS patients

Here are some important facts to know about the Indian Government's National Program for Rare Diseases (NPRD) can help aHUS patients.

National Program for Rare Diseases

This program, instituted by Ministry of Health and Family Welfare, offers financial help and access to care for rare disease patients. As of August 2024, 63 rare diseases were covered under this program. Atypical Hemolytic Uremic Syndrome (aHUS) is part of this list of diseases.

Three groups of rare diseases are covered by this program:

  1. Diseases that can be cured with a one-time treatment
  2. Diseases that need lifelong treatment but costs are low
  3. Diseases that need lifelong treatment and costs are very high
aHUS comes under the third group.

Support offered by the government

The government will fund up to Rs. 50 lakh per patient for treatment. The government may offer extra flexibility for Group 3 cases like aHUS, based on the patient’s situation. No GST or customs duty will be levied on rare disease drugs imported for treatment.

Centres of Excellence

The government has identified a list of Centres of Excellence (CoE) which would be the nodal agencies to facilitate treatment under this program. Here is a list of the CoEs in different cities in India.

Things to do to avail the support from the government

Patients must speak to their doctors about registering with the NPRD at a Centre of Excellence. This would involve medical evaluation to confirm the diagnosis, some documentation which would included some tests, medical history etc. There is an application form that would need to be filled in. Once that is submitted, then patients would need to wait for the approval to come.


List of Centres of Excellence under NPRD

Here is a list of the Centres of Excellence listed under the National Program for Rare Diseases (NPRD). These centres are authorised to approve any treatment for rare disease patients under the NPRD where a fund of up to Rs. 50 lakhs is granted.

  • All India Institute of Medical Sciences, New Delhi
  • Maulana Azad Medical College, New Delhi
  • Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow
  • Post Graduate Institute of Medical Education and Research, Chandigarh
  • CDFD with Nizam Institute of Medical Sciences, Hyderabad
  • King Edward Memorial Hospital, Mumbai
  • Institute of Post-Graduate Medical Education and Research, Kolkata
  • Center For Human Genetics (CHG) with Indira Gandhi Hospital, Bengaluru
  • All India Institute of Medical Sciences, Jodhpur
  • Institute Of Child Health and Hospital for Children, Chennai
  • Government Medical College, Thiruvananthapuram
  • All India Institute of Medical Sciences, Bhopal

Monday, September 15, 2025

Eculizumab Launched in India

In a long-awaited welcome development, Eculizumab has been formally launched in India. In a press release issued recently, AstraZeneca, the company that acquired Alexion Pharmaceuticals, the manufacturer of the drug (brand name: Soliris) said, "Until now, limited awareness, diagnosis, and access to targeted therapies have contributed to prolonged hospitalisations and increased complications for those affected. The availability of Eculizumab marks a breakthrough in the standard of care."

For aHUS patients in India, this is a tremendous breakthrough in their collective journey. Until now, the drug was either not available or available only by importing it specifically for their use - a very arduous and complicated process.

Hopefully now, that would be a thing of the past. While there is still some lack of clarity on how the drug can be accessed and the cost at which it is available (which the aHUS India Foundation is working closely with the company on getting more information about), at least the delays in importing the drug would not be there.

The aHUS India Foundation strongly urges patients to speak to their doctors on their treatment plans and how they would change with the availability of the drug.

The Foundation also urges doctors with aHUS patients to be aware that the drug is now available and to please reach out to the company or us (ahusindia@gmail.com) and get access to the drug for your patients.

We, at the aHUS India Foundation are grateful to the company and the regulatory authorities for their efforts in making the drug available in India.

Saturday, September 6, 2025

aHUS India - Patient Journeys

Often beyond all the news and information, real patient journeys get hidden. These journeys are however the real story. Individual stories of pain, suffering and yes - even in the midst of all the despair - hope. We, at the Atypical HUS India Foundation are bringing to you such stories where patients have fought back to take control of their lives.

In the first such story, we bring to you a young male from Mumbai who was diagnosed with this disease out of the blue, with no prior warning. This diagnosis turned his life upside down. And yet, he continues fighting, even today in the hope that one day he will get access to a complement inhibitor which will enable him to lead a normal life.



Thursday, July 3, 2025

aHUS Simplified - Webinar Summary

Here is a summary of what was discussed in the webinar we held on 30 June:


Dr. Arvind Bagga (Pediatric Nephrologist, Indraprastha Apollo & Professor Emeritus, AIIMS Delhi)

Presented a foundational explanation of the immune system and its two parts – innate and adaptive immunity.

Focused on the complement system, especially the alternative pathway which is rapidly activated and can become overactive in aHUS.

Explained how regulatory proteins (Factor H, Factor I, CD46) function as brakes on the complement system; their failure leads to uncontrolled immune activation and damage to the body’s own tissues.

Outlined that aHUS leads to microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury – hallmark features of thrombotic microangiopathy (TMA).

Described diagnostic process, stressing it is largely one of exclusion, and explained the limited utility of low C3 as a consistent diagnostic marker.

Detailed genetic causes (autosomal recessive or dominant mutations in Factor H, I, CD46, C3, DGKE) and role of Factor H autoantibodies in Indian children.

Reiterated that plasma exchange is particularly useful in anti-Factor H autoantibody cases, but not a substitute for complement inhibitors like Eculizumab.

Urged greater awareness among pediatricians and hematologists for early diagnosis and referral.

Dr. Valentine Lobo (Senior Nephrologist, KEM Hospital, Pune)

Highlighted the evolving nomenclature, noting that 'aHUS' is now better classified under complement-mediated thrombotic microangiopathies (TMAs).

Shared his extensive clinical experience in adults: common triggers include pregnancy (40% of his cohort), snake bites (16%), transplants, drugs, and autoimmune diseases.

Discussed difficulty in distinguishing primary (genetic/autoimmune) vs secondary aHUS (triggered by known factors). Emphasized that genetic testing is not always required for secondary aHUS.

Provided criteria for diagnosis in adults – anemia, thrombocytopenia, acute kidney injury – and how it's often missed due to overlapping symptoms with more common illnesses.

Outlined findings from his cohort of 121 patients over 12–15 years and the role of biopsy in complex cases (e.g., post-transplant or late presentation).

Warned against unregulated dosing once complement inhibitors become available, emphasizing the importance of making an accurate diagnosis first.

Described current and past clinical trials in India (Crolimab, Iptacopan), with India contributing significantly due to high patient volumes.

Stressed the urgent need for reference labs for anti-Factor H testing, genetic interpretation expertise, and establishment of structured treatment pathways at COEs.

Shiv (Patient Speaker)

Shared a deeply personal account of living with aHUS: first symptoms appeared at age 22 with hematuria, jaundice, and high BP; was quickly placed on dialysis.

Received plasma exchange but sustained irreversible kidney damage; underwent 11 months of dialysis before kidneys partially recovered (~40% function).

Maintained partial function from 2014–2024, after which kidney function again declined and he resumed dialysis.

Only recently diagnosed with a CFI mutation after undergoing genetic testing, unavailable during his initial episode.

Highlighted emotional toll, work-life challenges, and physical exhaustion from dialysis, but also stressed importance of family support and community.

Encouraged others to explore India’s National Rare Disease Policy and register under the scheme through COEs to gain access to future therapies.

Expressed hope for access to eculizumab or ravulizumab in India, required before his planned kidney transplant.

Audience Q&A (with Drs. Bagga & Lobo)

Recurrent disease post-transplant is likely due to a pathogenic complement mutation – full genetic workup recommended (gene sequencing, CNV, haplotype, and therapy prediction).

Plasma exchange is superior to plasma infusion in acute settings due to higher volume clearance of antibodies and regulators.

Withdrawal of eculizumab therapy has been studied: low relapse rates in patients with no detected mutation, but higher in those with pathogenic mutations.

Typical vs Atypical HUS vs TTP: History of diarrhea suggests typical HUS (Shiga toxin); low platelets with less severe kidney failure points to TTP; aHUS is a diagnosis of exclusion.

Doctors called for co-specialty awareness (hematologists, internists) to avoid misdiagnosis and delays in therapy.

Announced development of a point-of-care test (similar to a pregnancy test) for anti-Factor H antibodies in collaboration with Spanish researchers and Indian labs (THSTI, ICMR).

Stressed need for strong guidelines to ensure correct dosing and avoid cost-driven under-treatment once drugs are introduced.

Kamal Shah (Moderator & Host; Founder, aHUS India Foundation)

Introduced the webinar as the first of its kind in India for aHUS patients, highlighting the historical lack of access to treatment.

Expressed hope due to recent advancements and encouraged patients to engage by registering with the foundation, sharing their stories, and subscribing to the newsletter.

Explained that aHUS was previously seen as a double misfortune – genetic and geographic – but now there's hope with new treatments becoming available in India.

Described the Indian government's National Policy for Rare Diseases, which offers financial support of up to ₹50 lakh for patients under Category 3 (treatable but high-cost diseases like aHUS).

Detailed the need for patients to register with designated Centers of Excellence (COEs) through their doctors to access this scheme.

Listed 12 COEs and provided the foundation’s website (www.hus.in) for further information.

International Guests Acknowledged

Linda Burke (USA), Jeff Schmidt (USA), and Margriet Eygenraam (Canada) who had joined the webinar from various parts of the world were acknowledged for their contributions to the global aHUS community. 

Recognized for their leadership and continued support to Indian patients through international collaboration and awareness.

Closing Remarks

Kamal Shah reiterated key calls to action: register with the aHUS India Foundation, subscribe to the newsletter, and submit patient stories.

Appreciated the participation of all speakers and attendees and promised to conduct more such webinars.

Thanked AstraZeneca for supporting the event, and the Kidney Warriors Foundation for its consistent partnership.